menu search

OMER / Omeros: The Weight Of The Wait, A Conundrum

Omeros: The Weight Of The Wait, A Conundrum
Omeros' OMIDRIA sale has substantially improved its financial prospects. Omeros' CRL gangplank is agonizing for shareholders as they wait for FDA response to its type A meeting. Read More
Posted: May 2 2022, 22:18
Author Name: Seeking Alpha
Views: 111425

OMER News  

Omeros to terminate kidney disease trial as therapy fails late-stage study

By Reuters
October 16, 2023

Omeros to terminate kidney disease trial as therapy fails late-stage study

Omeros Corp said on Monday it will discontinue a trial studying its therapy to treat a type of kidney disease after it failed to meet the main goal of more_horizontal

Omeros Corporation - Still Looking Too Risky For A Buy Rating

By Seeking Alpha
July 21, 2023

Omeros Corporation - Still Looking Too Risky For A Buy Rating

Omeros Corporation's share price has seen significant run-ups in recent months despite disappointing first quarter results in 2023 and the company's l more_horizontal

Omeros Announces Webcast Details for Annual Meeting of Shareholders

By Business Wire
June 21, 2023

Omeros Announces Webcast Details for Annual Meeting of Shareholders

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareh more_horizontal

Why Shares of Omeros Dropped on Monday

By The Motley Fool
June 12, 2023

Why Shares of Omeros Dropped on Monday

The company's lead therapy, Narsoplimab, has not yet been approved. As of the first quarter, Omeros had $371.4 million in cash. more_horizontal

Omeros Corporation (OMER) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 9, 2023

Omeros Corporation (OMER) Q1 2023 Earnings Call Transcript

Omeros Corporation (NASDAQ:OMER ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations G more_horizontal

Omeros Corporation (OMER) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 13, 2023

Omeros Corporation (OMER) Q4 2022 Earnings Call Transcript

Omeros Corporation (NASDAQ:OMER ) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relatio more_horizontal

Why Omeros Stock Bolted Higher This Week

By The Motley Fool
February 9, 2023

Why Omeros Stock Bolted Higher This Week

A $200 million milestone payment sparked a rally in the biopharma's shares this week. more_horizontal

Omeros: $200M Added To The Company's Balance Sheet, Upgrading To Strong Buy

By Seeking Alpha
February 8, 2023

Omeros: $200M Added To The Company's Balance Sheet, Upgrading To Strong Buy

Omeros Corporation's stock has rallied 66% on Feb 6th based on the milestone payment of $200M, which eliminated the potential cash runway overhang som more_horizontal


Search within

Pages Search Results: